Axxess Pharma, AXXE, Profile, Summary

Axxess Pharma, AXXE, Profile, Summary

Axxess Pharma (AXXE) is a specialty Health Care Products Company dedicated to improving health and quality of life by offering select medicines, nutritional supplements and over the counter remedies all across the Americas. Axxess's goal is to bring additional products to the market and provide new, innovative options for better health spanning areas such as high cholesterol, blood pressure, acute pain as wells as nutritional supplements.

Axxess Pharma is dedicated to providing a wide range of products to improve the lives of patients and consumers worldwide.
Axxess Pharma intends to market these products with affordable pricing and widespread availability. The products are targeted to improve health-related conditions including several forms of iron deficiency, bone loss, rheumatoid arthritis, migraine headaches, urinary tract infections, infant cradle cap, joint pain and much more. Axxess Pharma will continue to tap the well of innovation to develop ever-more effective and affordable treatment options for the patients.

Axxess Pharma Signed an Exclusive World-Wide License to Market and Sell TapouT Brand Vitamins & Minerals Pain Relief and Muscle Recovery Products. http://shop.tapout.com/

Sources: The Company, OxBridge Research, OTCKING, DailyStockDeals, OTCstockIQ

Don't miss the NEXT premium Alert! Sign-up, Get Alerts,MakeMoney!®

Disclaimer/Disclosure: we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.

Want to get your company featured? or have questions/comments, please don't hesitate to contact the Editor. editor [@] OxBridgeResearch.com

Vitamins, proteins, supplements, bone loss, hair loss, weight loss, migraine, pain in the ass, pussy pain, erection problems, ejaculation, low labido, sex desire, high sex drive, quick erection, long lasting erection, quick orgasm, long lasting orgasm, multiple orgasm.

FDA's surprise Valentine Gift to WOMEN!

FDA's surprise Valentine Gift to WOMEN!

Who says FDA doesn't know anything about romance? We are pretty sure nothing like this ever happened before, the greatest romantic gesture in the history of FDA and the timing was priceless!

On Valentine eve FDA delivered a surprise gift, Ladies: its NOT long stem Roses, something Better! FDA said YES! to Gel. FDA has approved BioSante's Bio-T-Gel. BPAX estimates the market for Male Dysfunction drugs in the US alone is $1.2 Billion Dollars.

We alerted our members on Jan 17th when the stock was trading near the 52WK Lows, our headline read “BPAX shareholders wonder if there is a Gel for stock dysfunction!”

Well, there you have it, FDA answered the prayers and BPAX is UP a whopping 107% ! our members are ecstatic. Are you Gellin'?

Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®
we receive compensation from companies we feature, Always Read the full Disclosure/Disclaimer. Thanks.

Improving women's health and sex life, Bionovo, BNVI

Bionovo, BNVI, Profile, Summary
Bionovo (BNVI) a clinical-stage drug discovery and development company, focuses on the development drug candidates in the areas of women's health and cancer. The company's drug development process utilizes botanical sources used in traditional Chinese medicine to produce biologically active compounds.
Bionovo's lead drug candidate, Menerba, which completed phase 2 clinical trail and progressing into phase 3.
Improving Women’s Health
40 million women in America are of menopausal age, an estimated 75% to 85% experience significant and unpleasant side effects due to declining and fluctuating hormone levels. These problems include vaginal dryness, depression and weight gain. Existing therapies represent a multi-billion dollar market. Bionovo is striving to provide a safe, reliable, and clinically proven therapy to fill this unmet need.
The company also develops Bezielle, an oral anti-cancer agent that completed two separate phase 1 clinical trails for the treatment of advanced breast cancer. Seala, a preclinical drug candidate for the treatment of post-menopausal vulvar and vaginal atrophy.
Conquering Cancer
Breast cancer is the second leading cause of cancer deaths in the United States, and more than 200,000 new cases are diagnosed each year. As a result, breast cancer takes more than 40,000 lives annually.
The company successfully raised funds and appointed new executives and board members. The stock is trading near 52WK LOWS could bounce back, keep an eye!
Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®
we receive compensation from companies we feature. Always Read the full Disclosure/Disclaimer. Thanks.